The first B-cell depleting agent, rituximab, was approved in 1997 for combination treatment of CD20+ B-cell non-Hodgkin lymphoma ([@b8-btt-1-325]). In 2001, based on the premise that autoantibodies derived from B-cell-derived antibody-secreting cells were closely associated with disease pathogenesis, the first study was published showing promising effects of rituximab in the treatment of patients with rheumatoid arthritis (RA) ([@b11-btt-1-325]). Because circulating autoantibodies are a common feature in several other auto-immune diseases as well, B-cell depleting therapies are now widely used in clinical trials assessing the safety and efficacy of this treatment in a variety of systemic and organ-specific auto-immune diseases ([Table 1](#t1-btt-1-325){ref-type="table"}).

Rituximab is a therapeutic agent categorized in the group of "biologicals". It is a monoclonal antibody directed against the CD20 transmembrane protein present on B-cells. It is generally accepted that the CD20 protein functions as a channel regulator of ion influx ([@b15-btt-1-325]) and that this membrane-bound protein is specifically found on the membrane of B-cells but is not expressed on stem cells nor on terminally-differentiated plasma cells.

The current review addresses the expanding role of B-cell depleting therapy in the treatment of RA patients in rheumatologic practice. In this review, we focus on the role of B-cells in the pathogenesis of RA, on pharmacological aspects of rituximab and on results from clinical trials investigating rituximab in RA patients, including safety, efficacy and quality of life studies.

Management of RA
================

Prominent symptoms of RA are symmetrical arthritis of multiple joints, mostly of the hands and feet, typically accompanied by morning stiffness. In the long term, RA leads to joint destruction and increased disability ([@b23-btt-1-325]). Because RA patients have a systemic, chronic and progressive disease, they usually require long-term immunosuppressive treatment. Generally, treatment of RA patients is instituted with a single or combination of Disease Modifying Anti-Rheumatic Drugs (DMARDs), of which methotrexate is currently seen as the anchor drug. Several studies have shown that failure rates for conventional DMARD therapy can accumulate over a follow-up period of 5 years to up to 75% ([@b36-btt-1-325]; [@b3-btt-1-325]; [@b55-btt-1-325]). In a Dutch treatment strategy study, the so-called BeSt study, which investigated treatment strategies in early RA, approximately 25% of the patients failed on step-up or combination DMARD treatment after 2 years of follow-up ([@b19-btt-1-325]). From this perspective, the majority of RA patients will eventually fail conventional DMARD therapy, after which patients are candidates for treatment with biologicals, notably with anti-cytokine treatment directed against TNF (tumor necrosis factor) (Infliximab^®^, Etanercept^®^, Adalimumab^®^). Currently most of the evidence for treating DMARD refractory RA is derived from treatment with TNF-blocking agents, which were the first biologicals to be approved in this category of patients ([@b37-btt-1-325]; [@b62-btt-1-325], [@b61-btt-1-325]; [@b5-btt-1-325]). The success of specifically targeting TNF cytokines in RA patients has augmented the efforts to specifically target other components of the immune system in RA patients. Furthermore, it is estimated that one third of the RA patients eventually fail TNF-blocking agents ([@b54-btt-1-325]), which supports the need for new therapies to control disease activity in refractory RA. Newly emerging biologicals include B-cell depleting agents, ie, anti-CD20 monoclonal antibodies (rituximab, HuMax-CD20^®^) and anti-CD22 monocolonal antibodies (Epratuzumab^®^), T-cell activation blockade through monoclonal antibodies against CTLA-4 (Orencia^®^, Abatacept^®^) and IL-6 receptor blockade (Tocilicumab^®^, Actemra^®^). While most of these biologicals are currently investigated in phase II and III trials or have recently been approved, the B-cell depleting agent rituximab has now been approved for treating RA patients refractory to TNF-blockade since 2006 ([@b1-btt-1-325]; [@b35-btt-1-325]). The success of B-cell depleting therapy in RA patients has underscored the important role of B-cells in the pathophysiology of RA.

B-cells are critically involved in the pathogenesis of RA
=========================================================

RA shares a common immune abnormality with other rheumatic diseases, such as systemic lupus erythematodes (SLE), Sjogren's syndrome (SS) and Wegener granulomatosis (WG), namely the production of autoantibodies ([@b23-btt-1-325]). Since the discovery of autoantibodies more than 50 years ago ([@b44-btt-1-325]; [@b22-btt-1-325]), these circulating autoantibodies are the key argument that B-cells play a pivotal role in the pathophysiology of many rheumatic diseases. However, B-cells can contribute in several ways to the development of rheumatic diseases. First, B-cells are precursors of (auto-)antibody-secreting plasma cells. Secondly, they function as (auto-)antigen presenting cells, and, additionally, activated B-cells also produce cytokines (TNF-α, IL-6) that may influence the function of antigen-presenting dendritic cells. Thirdly, activated B-cells express costimulatory molecules, essential in the interaction with effector T-cells ([@b9-btt-1-325]).

Importantly, the detection of rheumatoid factor autoantibodies (RF) and anti-cyclic citrullinated protein autoantibodies (ACPA) are very specific findings in RA patients ([@b17-btt-1-325]; [@b40-btt-1-325]; [@b56-btt-1-325]). RF autoantibodies are directed against the Fcγ-tail of immunoglobulins and can form immune complexes. ACPA are directed against citrullinated peptides, which originate from the enzymatically conversion of arginine residues of proteins ([@b60-btt-1-325]). RA patients with circulating ACPA develop more joint damage over time ([@b24-btt-1-325]) and respond less favorably to anti-rheumatic therapies ([@b2-btt-1-325]).

B-cell hyperactivity is considered a hallmark of autoimmune disease, as was shown in SLE and SS ([@b34-btt-1-325]; [@b33-btt-1-325]; [@b21-btt-1-325]). Recently, a comprehensive, observational study in blood, bone marrow and synovium of RA patients showed similar characteristics of B-cell hyperactivity ([@b51-btt-1-325]). Moreover, infiltration of B-cells and plasma cells are commonly observed in synovial biopsies from RA patients ([@b28-btt-1-325]; [@b57-btt-1-325]; [@b59-btt-1-325]). Still, the exact role of autoantibodies in the pathophysiology of RA remains unclear. Clinical studies from the beginning of 21st century already provided the important insight that eliminating RF autoantibodies by plasmapheresis or absorption by a column that specifically bind IgG (Prosorba) was unsuccessful in decreasing disease activity in RA ([@b18-btt-1-325]). Therefore, these observations suggest that the efficacy of B-cell depleting strategies in RA is based upon interference with the cellular functions of B-cells and/or the inhibition of differentiation into autoantibody producing cells.

B-cell depleting therapies
==========================

B-cell depletion can be achieved either by non-specific, high dose immunosuppression ([@b48-btt-1-325]; [@b58-btt-1-325]) or by specifically targeting B-cell specific membrane proteins, such as CD20 and CD22 ([@b20-btt-1-325]; [@b45-btt-1-325]). High dose chemotherapy has been shown to induce significant but temporary improvement of disease activity in RA patients ([@b47-btt-1-325]), which was associated with significant and long-lasting T-cell suppression in peripheral blood ([@b58-btt-1-325]). Therefore, specific targeting of merely B-cells is a less toxic and less rigorous therapy, possibly with similar efficacy in RA. In this respect, membrane proteins specific for B-cells are ideal targets for B-cell depleting therapies. [Figure 1](#f1-btt-1-325){ref-type="fig"} shows several B-cell specific and non-specific membrane-bound proteins during B-cell development. It is obvious that targeting any of the B-cell specific proteins will target a large part but not the complete B-cell population. Currently, three agents, rituximab, HuMax-CD20 and epratuzumab, have been investigated to induce specific B-cell depletion but only the use of rituximab has been reported in RA patients.

Pharmacological aspects of rituximab treatment in RA
====================================================

Pharmacodynamic properties of rituximab are related to its specificity for the CD20 membrane protein, found on the surface of B-cells. Although not fully elucidated, the cytotoxic effects of rituximab on CD20+ cells appear to involve complement-dependent cytotoxicity, complement-dependent cellular cytoxicity, antibody dependent cellular cytotoxocity and induction of apoptosis ([@b6-btt-1-325]; [@b38-btt-1-325]; [@b46-btt-1-325]). The time to recovery of B-cells in peripheral blood is generally between 6 and 9 months ([@b12-btt-1-325]; [@b29-btt-1-325]; [@b43-btt-1-325]). Recently, our group reported on the depleting effects of rituximab in peripheral blood, bone marrow and synovium of RA patients ([@b53-btt-1-325]). Rituximab led to a rapid and complete depletion of all B-cells in peripheral blood. It was also shown that CD20+ B-cells in bone marrow were completely depleted at 12 weeks after therapy, in keeping with a small study in 5 RA patients by [@b30-btt-1-325]. Still, not all CD19+ B-cells were eliminated in bone marrow as pre-B-cells and CD20− plasma cells were not targeted. Lastly, we showed for the first time that also in synovium all CD20+ B-cells, but not all CD79a+ B-cells, were eradicated ([@b53-btt-1-325]). The latter is in line with the findings of a previous study showing incomplete depletion of CD22+ B-cells in synovium ([@b59-btt-1-325]). In summary, it can be concluded that one treatment course consisting of 2 infusions of rituximab is able to completely deplete the subset of CD20+ B-cells, but not other B-cell lineage cells such as plasma cells in bone marrow and synovium. Of note, data on B-cell counts after rituximab treatment should be carefully interpreted because recent studies have shown that rituximab can mask the CD20 epitope for other diagnostic anti-CD20 monoclonal antibodies used to identify B-cells ([@b50-btt-1-325]; [@b52-btt-1-325]). Therefore, it is crucial that other pan-B-cell markers, eg, CD19 or CD79a, are also reported.

One study has reported on the pharmacokinetics of 2 dosages of 1g rituximab in 107 RA patients, of whom 37 patients also received intravenous cyclophosphamide and 36 patients oral methotrexate ([@b41-btt-1-325]). This study showed rituximab had a distribution volume of 45 mL/kg with an average clearance rate of 276 mL/day. The half-life of rituximab after the first infusion was 2.4 days and after the second infusion 19.7 days. This difference in half-lifes can be explained by differences in the distribution of rituximab from the intravascular to the extravascular compartment and to some extent by the different rate of elimination of the rituximab after binding to the CD20 membrane protein. The latter contrasted to data from lymphoma patients, in whom baseline B-cell values did affect clearance rate and distribution volume of rituximab. Importantly, this study also showed that clearance rate and distribution of rituximab were related to patients' body surface area (BSA), but that BSA could only explain 20% of the variability in clearance rate between patients. Furthermore, a study on the effects of BSA-adjusted dosage of rituximab in these patients showed only modest differences in exposure, indicating that BSA-adjusted dosage schemes for RA patients probably do not improve pharmacokinetic characteristics of rituximab ([@b41-btt-1-325]).

Efficacy of rituximab in RA
===========================

Following several open-label studies of rituximab treatment showing promising improvements in patients with RA ([@b11-btt-1-325]; [@b31-btt-1-325]), Edwards et al conducted a randomized, placebo-controlled, multicenter trial to assess the efficacy of rituximab as a single agent or in combination therapy with methotrexate or cyclophosphamide. The study assessed 161 patients with RA, and compared the rituximab regimens with methotrexate alone ([@b13-btt-1-325]). The primary endpoint was defined as an ACR50 response (ie, a 50% or greater improvement in the signs and symptoms of RA, as defined by the American College of Rheumatology \[ACR\]) within 24 weeks. In this pivotal trial, 33% of the patients treated with rituximab alone achieved an ACR50 response, compared with 13% in the methotrexate group. The differences were even larger when combination therapy was used: 41% and 43% of patients achieved an ACR50 response when treated with rituximab in combination with methotrexate and cyclophosphamide, respectively. Naturally, more patients achieved an ACR20 response (20% improvement) in this trial, the main results of which are summarized in [Figure 2](#f2-btt-1-325){ref-type="fig"}. Treatment with rituximab, particularly when combined with methotrexate, remained more efficacious than methotrexate alone for at least 1 year. In addition, extension studies showed sustained benefit from a single course of rituximab for up to 2 years ([@b49-btt-1-325]).

Further evidence for the efficacy of rituximab in RA comes from the Dose-Ranging Assessment International Clinical Evaluation of rituximab in Rheumatoid Arthritis (DANCER) trial, which examined the efficacy of different doses of rituximab (500 mg bd vs 1000 mg bd on days 1 and 15) and glucocorticoids in combination with stable doses of methotrexate ([@b14-btt-1-325]) ([Figure 2](#f2-btt-1-325){ref-type="fig"}). This trial confirmed the previous positive effects of rituximab on RA disease activity. There was no difference in primary outcomes (ACR20 and ACR50 responses) between medium (500 mg) and high (1000 mg) doses of rituximab. However, using more stringent outcome measures (eg, ACR70 response or remission defined by disease activity score) a trend in favor of high doses was observed. Furthermore, more patients developed circulating human anti-chimeric antibodies (HACA) when treated with medium doses (4.9% vs 2.7%). The DANCER study also demonstrated that corticosteroids administered during the first 15 days of therapy (around the doses of rituximab) did not contribute to efficacy. However, intravenous methylprednisolone (100 mg iv before rituximab infusions) significantly reduced the frequency of acute infusions reactions at the 1st infusion (35% in the glucocorticoid-placebo group versus 25% in the glucocorticoid group), but not of the 2nd infusion at which time significantly fewer infusions reactions occurred in general (5.6% in both groups).

More recently, the Randomized Evaluation of Long-term Efficacy of rituximab (REFLEX) study also showed rituximab to be highly effective in patients with RA who had experienced an inadequate response to one or more TNF-blocking agents ([@b7-btt-1-325]). In this trial 520 refractory RA patients were randomized to methotrexate alone or the combination of methotrexate with rituximab. Although this study defined its primary endpoint as an ACR20 improvement (summarized in [Figure 2](#f2-btt-1-325){ref-type="fig"}), the significantly larger proportion of RA patients that achieved an ACR50 improvement with rituximab and methotrexate (27%) as compared to methotrexate alone (5%) is more illustrative for comparison and confirms the efficacy achieved in the first trial of Edwards et al. Moreover, this study was able for the first time to measure a trend towards slower radiographic progression within 24 weeks in patients treated with rituximab (change in total Genant-modified Sharp score of 0.6 ± 1.9) in comparison to the methotrexate alone group (change in total Genant-modified Sharp score of 1.2 ± 3.3; p = 0.17). This was further corroborated after 1 year, when progression was significantly lower in the rituximab-treated group (change in radiographic score: 2.31 vs 0.99; p = 0.004) (Keystone, [@b14-btt-1-325]).

Interestingly, preliminary data indicate that RA patients can be successfully retreated with rituximab. The efficacy of repeated courses of rituximab did not seem to differ from the first treatment course ([@b42-btt-1-325]; [@b26-btt-1-325]).

Safety and tolerability
=======================

Rituximab has been used in the general hematological practice for more than 10 years. Long-term safety is well established in these patients: no increased incidence of infections has been observed and most infections were typical of those common in normal hosts ([@b39-btt-1-325]). Safety data for rheumatologic patients are thus far limited and conclusions can only be drawn for the short-term adverse events. Most of the side effects are seen during the intravenous administration and consist of mild symptoms (nausea, fever, headache, myalgia). In the DANCER phase-II trial reported 38% (73 of 192 patients) of the RA patients experienced infusion-related side effects while in the REFLEX-trial this was 23% (72 of 308 patients) using 1000 mg rituximab. Significantly fewer side effects were observed at the second infusion: in DANCER 10% (19 of 192 patients) and in REFLEX 8% (26 of 308 patients). This can be explained by desensitization due to the fact that rituximab can still be measured in serum at low concentrations when the second infusion is administered. Furthermore, a study evaluating the concomitant administration of corticosteroids before the infusion of rituximab showed that corticosteroids did not affect the outcome of patients, but did decrease the incidence of infusion-related side effects in one third of the patients ([@b16-btt-1-325]).

With respect to infectious complications ([Table 2](#t2-btt-1-325){ref-type="table"}), a non-significant increased incidence of 35% was reported in rituximab treated group versus 28% in the placebo group from the DANCER study. The type and severity of infections were similar in both groups, mostly being respiratory tract infections (7%), urinary tract infections (3%) and nasopharyngitis (6%). Serious infections were not common and occurred in 1%--2% of the patients. When accumulating data from the REFLEX-trial, an incidence of infections of 41% was observed as compared to 38% in the placebo group. The calculated rate of infection per 100 patient years was actually lower in the rituximab treated group (154.6 in the placebo group versus 138.2 infections per 100 yrs in the rituximab treated group). Regarding serious infections there was a trend to a higher incidence in patients treated with rituximab (3.7 in the placebo group versus 5.2 infections per 100 years in the rituximab treated group). Collectively, these short-term data suggest that a single treatment course with rituximab does not increase the incidence of infectious complications, which suggests that during B-cell depletion the innate immune system as a "first-line defense", including natural killer cells and T-cells, as well as circulating antibodies and long-lived plasma cells provide adequate protection to exogenous antigens ([@b39-btt-1-325]).

Lastly, B-lymphocyte depletion is an anticipated side effect of rituximab and the time to reconstitution differs for each patient and for each underlying rheumatic disease. The mean time to reconstitution is around 6--9 months ([@b10-btt-1-325]). A decrease of serum concentration of immunoglobulins (IgG, IgM, IgA) below normal values seldom occurs. Also, long-term humoral memory derived from long-lived plasma cells, as measured by serum antibodies against the recall antigen tetanus toxoid, does not seem to be affected by a single treatment course of rituximab.

Patient-focused perspectives
============================

Few studies so far have addressed patients' satisfaction and acceptability of rituximab treatment, although new data will appear. One spin-off study from the REFLEX-trial investigated quality of life as measured by the SF-36. This study showed that rituximab resulted in a significantly greater improvement in quality of life scores on all 8 domains of the SF-36 ([@b27-btt-1-325]). In addition, two cost-analysis studies performed by the Health Economics and Strategic Pricing of F. Hoffmann-La Roche ([@b4-btt-1-325]; [@b32-btt-1-325]), the pharmaceutical company producing rituximab, showed by a Markov Model that rituximab combined with methotrexate could achieve a gain of 0.48--0.63 Quality Adjusted Life Years (QALYs) as compared to current practice for refractory RA patients, which included TNF-blocking treatment. Importantly, these analyses compared treatments over an average time of approximately 18.5 years. Clearly, these studies need to be reproduced with adequate control groups as well as by independent groups, to enable relevant socioeconomic evaluations.

Conclusions
===========

Anti-CD20-mediated B-cell depletion by rituximab has proven to be a valuable expansion of the therapeutic armamentarium in the rheumatologic practice. Several studies have now established its efficacy and safety for treating refractory RA patients. Based on the evidence from three large randomized trials, rituximab treatment is a treatment option for RA patients failing TNF-blocking therapy. Future studies will have to show whether B-cell depletion is superior to TNF-blocking therapy in earlier stages of disease. In addition, the exact mechanism through which rituximab treatment results into clinical improvement still needs to be clarified. Recent studies have made it clear that depletion of CD20+ B-cells has led to significant decreases of autoantibody titers, but the biologic relevance of these observations is still unclear. Undoubtedly, as rituximab will be more and more prescribed by rheumatologists, further insight into the effects of B-cell depletion will be revealed. Lastly, studies analyzing cost-effectiveness will determine for a large part the availability of rituximab for RA patients in the near future and studies defining predictive factors of responsiveness to rituximab may therefore be of high importance. Recently, one study identified predictive determinants in serum and synovium of RA patients who have a high a-priori change to achieve a good response upon rituximab treatment ([@b53-btt-1-325]). Because of increasing expenses to provide biologic treatments, such as rituximab, to RA patients, these studies obviously need to be further substantiated.
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###### 

Diseases associated with autoantibodies and the usage of rituximab

  Autoimmune diseases             Target organ(s)             Rituximab treatment under investigation?   Inflammatory diseases          Target organ(s)          Rituximab treatment under investigation?
  ------------------------------- --------------------------- ------------------------------------------ ------------------------------ ------------------------ ------------------------------------------
  Rheumatoid arthritis            Joints                      yes                                        Henoch-Schonlein purpura       Vasculature, kidney      yes
  Systemic lupus erythematosus    Systemic                    yes                                        Chronic graft rejection        Graft                    yes
  Sjogren's syndrome              Salivary gland              yes                                        Immunoglobulin A nephropathy   Kidney                   no
  ANCA-associated vasculitis      Vasculature                 yes                                        Atopic dermatitis              Skin                     no
  Antiphospholipid syndrome       Vasculature                 yes                                        Asthma                         Lung                     no
  Idiopathic thrombocytopenia     Platelets                   yes                                        Allergy                        Skin, lung, gut          no
  Autoimmune haemolytic anaemia   Red blood cells             yes                                                                                                
  Guillain-Barre syndrome         Peripheral nervous system   yes                                        Systemic sclerosis             Connective tissue        no
  Autoimmune thyroiditis          Thyroid gland               yes                                        Multiple sclerosis             Central nervous system   no
  Pemphigus vulgaris              Skin, mucous membranes      yes                                        Lyme neuroborreliosis          Central nervous system   no
  Myasthenia gravis               Skeletal muscle             yes                                        Ulcerative colitis             Large intestine          no
  Chronic immune polyneuropathy   Peripheral nervous system   no                                         Interstitial lung disease      Lung                     no
  Type I diabetes                 Pancreatic islet cells      no                                                                                                 
  Addison's disease               Adrenal gland               no                                                                                                 
  Membranous glomerulopathy       Kidney                      no                                                                                                 
  Goodpasture's syndrome          Lung, kidney                no                                                                                                 
  Autoimmune gastritis            Stomach                     no                                                                                                 
  Pernicious anaemia              Stomach                     no                                                                                                 
  Primary biliary cirrhosis       Liver                       no                                                                                                 
  Dermatomyositis-polymyositis    Skeletal muscle, skin       no                                                                                                 
  Celiac disease                  Small intestine             no                                                                                                 

###### 

Rate of infectious events in two pivotal, double-blinded, randomized trials assessing efficacy of rituximab in RA patients

  DANCER trial (N = 209 vs 308)            Placebo (N = 149)       RTX 2 × 500 mg (N = 124)   RTX 2 × 1000 mg (N = 192)
  ---------------------------------------- ----------------------- -------------------------- -------------------------------
  Total patient years                      n.a.                    n.a.                       n.a.
  Incidence of infections                  28%                     35%                        35%
  Infections per 100 patient yrs           n.a.                    n.a.                       n.a.
  Serious infections per 100 patient yrs   3.19                    0                          4.74
  **REFLEX trial**                         **Placebo (N = 209)**                              **RTX 2 × 1000 mg (N = 308)**
  Total patient years                      82.1                                               134.6
  Incidence of infections                  38%                                                41%
  Infections per 100 patient yrs           154.6                                              138.2
  Serious infections per 100 patient yrs   3.7                                                5.2
